{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:11:17Z","timestamp":1778937077277,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008877","name":"Biosensors International Group Ltd Asia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019265","name":"Yuhan Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ahj.2026.107437","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:04:51Z","timestamp":1775059491000},"page":"107437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial"],"prefix":"10.1016","volume":"298","author":[{"given":"In Tae","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeong Ho","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Kyu","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Joon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Soo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Kyeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Ho","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Gyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeoh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Jin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Keuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Guk","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong-Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-3274","authenticated-orcid":false,"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107437_bib0001","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107437_bib0002","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107437_bib0003","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107437_bib0004","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107437_bib0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey","volume":"42","author":"Cao","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107437_bib0006","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrneph.2010.143","article-title":"Atherosclerosis in CKD: differences from the general population","volume":"6","author":"Drueke","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ahj.2026.107437_bib0007","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107437_bib0008","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107437_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review","volume":"7","author":"Colombijn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2026.107437_bib0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2026.107437_bib0011","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2013.05.023","article-title":"Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients","volume":"62","author":"Erlinge","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107437_bib0012","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jacc.2012.08.964","article-title":"Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial","volume":"60","author":"Erlinge","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107437_bib0013","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107437_bib0014","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.jcin.2016.06.051","article-title":"Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the Korean multicenter drug-eluting stent registry","volume":"9","author":"Lee","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2026.107437_bib0015","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","article-title":"Associations between chronic kidney disease and outcomes with use of Prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study","volume":"10","author":"Baber","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2026.107437_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012236","article-title":"Safety of dual-antiplatelet therapy after myocardial infarction among patients with chronic kidney disease","volume":"8","author":"Rymer","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107437_bib0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21037\/atm-24-85","article-title":"Nationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study","volume":"12","author":"Vasudeva","year":"2024","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ahj.2026.107437_bib0018","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical Trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107437_bib0019","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107437_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.ahj.2026.107437_bib0021","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2026.107437_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2796.2009.02204.x","article-title":"Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register","volume":"268","author":"Szummer","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.ahj.2026.107437_bib0023","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107437_bib0024","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1093\/eurheartj\/ehab533","article-title":"Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD","volume":"42","author":"Stefanini","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107437_bib0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4070\/kcj.2024.0232","article-title":"Ticagrelor monotherapy vs. Ticagrelor with aspirin in bleeding and cardiovascular events in acute coronary syndrome patients according to renal function: the subanalysis from the TICO trial","volume":"55","author":"Lee","year":"2025","journal-title":"Korean Circ J"},{"key":"10.1016\/j.ahj.2026.107437_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2017.11.013","article-title":"Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease","volume":"197","author":"Hwang","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107437_bib0027","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amjcard.2024.06.003","article-title":"One-month versus three-month dual-antiplatelet therapy in high bleeding risk patients with chronic kidney disease","volume":"225","author":"Mankerious","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2026.107437_bib0028","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12916-018-1145-0","article-title":"Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations","volume":"16","author":"Covic","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2026.107437_bib0029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107437_bib0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107437_bib0031","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107437_bib0032","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jcin.2021.06.028","article-title":"Ticagrelor or Prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate","volume":"14","author":"Wohrle","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2026.107437_bib0033","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.amjcard.2025.09.033","article-title":"Comparative effectiveness of prasugrel versus ticagrelor in dialysis-dependent end stage renal disease patients undergoing percutaneous coronary intervention","volume":"258","author":"Akbar","year":"2026","journal-title":"Am J Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:46:07Z","timestamp":1778935567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0002870326000992"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107437","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107437"}}